SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent leadership transition, the appointment of former Pfizer CMO Dr. Freda Lewis-Hall to its board, and anticipation surrounding upcoming Phase 2 data for its GAD program. The community remains polarized, with some highlighting the company's robust IP portfolio and institutional accumulation, while others express concerns over the stock's historical volatility and ongoing cash burn.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following significant insider selling by the CEO, sparking community frustration regarding management's long-term strategy and a desire for an acquisition. Despite these concerns, investors remain focused on the potential of the Casgevy commercial rollout and upcoming clinical data readouts across the firm's gene-editing pipeline.

Beamable Network is a decentralized compute infrastructure designed to power real games and digital experiences. Built by the team behind Beamable Inc.—a backend platform already serving over 95 live games—the network transforms compute into an open, tokenized marketplace. By combining distributed node operators, verifiable workloads, and blockchain incentives, Beamable Network provides scalable, cost-efficient infrastructure for any compute applications without dependence on centralized cloud providers.

Beamable Network Token

Beamable Network Token is experiencing heightened community interest driven by rapid price volatility and significant order book activity. Traders are actively tracking potential breakout patterns while debating the sustainability of the current momentum amid broader market speculation.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as the community debates its future price trajectory and utility, with many holders actively discussing the potential for a significant token burn as a key catalyst. Conversations are heavily polarized, featuring both optimistic bulls predicting major rallies and skeptics dismissing the asset as part of a recurring meme coin cycle.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh an upcoming Phase 3 readout for its hereditary angioedema therapy alongside significant volatility driven by high short interest and speculative sentiment. The community is actively debating the stock's potential as a binary event, with many focused on the interplay between clinical trial expectations, short-squeeze potential, and broader biotech sector momentum.

Chip

Chip is experiencing significant volatility and social media attention following its debut on major trading platforms, sparking a fierce debate among traders over whether it is a legitimate AI infrastructure utility or a speculative pump-and-dump scheme. The community is actively tracking support levels and debating the long-term potential of the token as it navigates price discovery and high trading volumes.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant management overhaul that includes the removal of CEO Peter Greenleaf and a total leadership restructuring led by the company's largest shareholder, Kevin Tang. The community is actively discussing the potential for an accelerated buyout and a strategic pivot to maximize shareholder value following these executive departures.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is facing intense scrutiny as a leadership transition to incoming CEO Josh D'Amaro highlights ongoing concerns regarding operational efficiency, content performance, and market stagnation. The community is actively debating the stock's long-term viability, weighing the company's streaming profitability and park demand against frustrations over persistent share price underperformance and polarizing creative strategies.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

$RETIRE is capturing significant community attention as a grassroots movement aimed at replacing traditional 401(k) systems, with supporters actively participating in weekly dollar-cost averaging to fuel long-term growth. Investors are currently focused on its potential for a major breakout, viewing the token as a life-changing financial alternative that stands in defiance of established, centralized retirement models.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors position for the upcoming May 31 PDUFA date for its ADHD candidate, CTx-1301, while closely monitoring for the imminent official grant of a U.S. patent. The community is actively debating the stock's volatility and the impact of potential manufacturing-related FDA inquiries versus the long-term potential of the firm's precision-timed release technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Chip Wilson said the board must be refreshed to empower a creative, brand-first experience.</li><li>He has nominated three independent directors to the board.</li><li>Wilson has called for the board to immediately declassify so that all directors are elected annually by shareholders. &nbsp;</li></ul>Lululemon founder Chip Wilson has launched a proxy fight by nominating three independent directors in an effort to remake the company’s board as the athletic-apparel retailer searches for a new chief executive.&nbsp;Wilson has also submitted a non-binding proposal calling for the board to immediately declassify, so that all directors are elected annually by shareholders.The Lululemon founder has nominated three candidates to the company's board, including former On Running co-CEO Marc Maurer, former ESPN Chief Marketing Officer Laura Gentile, and former Activision CEO Eric Hirshberg.He noted that CEO selection must follow a significant board change to ensure shareholders can trust that the right decision is made and that the new leader can succeed.“The recent CEO change announcement was the third total failure of board oversight, with no clear succession plan in place. Shareholders have no faith that this board can select and support the next CEO without input from a board with stronger product experience,” Wilson stated.“The Board must be refreshed so that a creative, brand-first experience is empowered,” he added.<h2 class="st-heading-2">CEO Departure Sparking Reset</h2>Earlier this month, Lululemon said its CEO, Calvin McDonald, will leave the company. The firm named its finance chief, Meghan Frank, and chief commercial officer, André Maestrini, as co-interim CEOs.The reset at retailers is becoming a sector norm as U.S. President Donald Trump’s tariffs have been hurting sales and eating into profits at several top retailers and wholesalers. Firms have also been seeing consumer demand slow as price pressures continue to weigh on consumers' pockets. Firms from Nestle and Walmart to Coty and Coca-Cola have all changed their CEOs this year.Shares in Lululemon have fallen nearly 44% so far in 2025.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-founder-launches-proxy-fight-to-change-baord/cL75M5PREx2">directly on Stocktwits.</a> &nbsp;

 A Lululemon corporate logo hangs on the front of their store in Brookfield Place on June 21, 2023, in New York City. (Photo by Gary Hershorn/Getty Images)

Lululemon Founder Targets Board Change Ahead Of CEO Search

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO. 

Equity

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

<ul class="summary-bullets"><li>The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.&nbsp;</li><li>The company is banking on strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes management.&nbsp;</li><li>For Q3, West Pharmaceutical reported adjusted and diluted EPS of $1.92, compared to $1.85 in the same period last year.&nbsp; &nbsp;</li></ul>Shares of West Pharmaceutical Services (WST) soared 12% on Thursday afternoon after the company increased its full-year earnings guidance after its third-quarter earnings beat Wall Street expectations.The Pennsylvania-headquartered company, which manufactures packaging components and delivery systems for injectable drugs and healthcare products, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results">raised</a> its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.It also hiked its full-year adjusted earnings per share (EPS) outlook to $7.06 to $7.11, up from $6.65 to $6.85, citing strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes regulation. In Q3, HVP components accounted for 48% of the company's total net sales.The firm, however, flagged that it continues to anticipate $15 million to $20 million in tariff-related costs this year.<h2 class="st-heading-2">CEO Remarks</h2>Chief Executive Eric M. Green stated that several factors drove HVP component sales in Q3. “First, elastomers for GLP-1s had strong growth and now account for 9% of total company sales. We benefit from our longstanding relationships as we partner with our customers in this market, supporting them as they expand their GLP-1 franchises…We expect this market to continue to evolve as there are a number of new early-stage trials seeking to expand the range of indications and treatments using GLP-1s,” Green said.He added that the company, which includes weight-loss drugmakers Eli Lilly and Novo Nordisk among its customers, is also collaborating with customers who are launching new GLP-1 molecules and generics.<h2 class="st-heading-2">Third Quarter Earnings</h2>For the third quarter (Q3), West Pharmaceutical reported adjusted and diluted EPS of $1.96, compared to $1.85 in the same period last year, and above an analyst estimate of $1.68, according to data from Fiscal AI. Net sales increased 7.7% year-over-year to $804.6 million in the quarter.The company reported a 16.3% increase in net sales of its HVP components to $390 million in the quarter. Contract-manufactured products segment net sales, meanwhile, rose 8% to $157.1 million, driven by increased sales of self-injection devices for obesity and diabetes.Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $390 from $350 while keeping an ‘Outperform’ rating on the shares following the earnings call.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WST">WST stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/59;" src="data:image/png;base64,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" width="619" height="59" alt="WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>WST stock is down by 5% this year but has risen over 8% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-stock-rises-after-adjournment-of-stockholders-meeting-to-discuss-proposed-merger-with-alcon/cLG4FXDR3rj">STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a West Pharmaceutical Services logo is seen on a mobile phone screen in front of a graph. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

XRMI
Global X S&P 500 Risk Managed Income

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XRMI News

XRMIGlobal X S&P 500 Risk Managed Income